Drugs / Olmesartan/amlodipine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01611077 | Jan → Dec 2012 | essential hypertension | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olmesartan/amlodipine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01611077 ↗ |
| Route | Oral | “then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days” NCT01611077 ↗ |